
Norah L. Johnson PhD, RN, CPNP
Marquette University, norah.johnson@marquette.edu

Karen Burkett
Cincinnati Children's Hospital Medical Center

Judy Reinhold
Cincinnati Children's Hospital Medical Center

Margaret W. Bultas
Saint Louis University

Follow this and additional works at: https://epublications.marquette.edu/nursing_fac

Part of the Nursing Commons

Recommended Citation
Johnson, Norah L. PhD, RN, CPNP; Burkett, Karen; Reinhold, Judy; and Bultas, Margaret W., "Translating Research to Practice for Children With Autism Spectrum Disorder: Part I: Definition, Associated Behaviors, Prevalence, Diagnostic Process, and Interventions" (2016). College of Nursing Faculty Research and Publications. 425.
https://epublications.marquette.edu/nursing_fac/425

Norah L. Johnson  
Assistant Professor, College of Nursing, Marquette University, Milwaukee, WI

Karen Burkett  
Pediatric Nurse Practitioner, Division of Developmental and Behavioral Pediatrics, APN Faculty Leadership Education in Neurodevelopmental Disabilities (LEND), Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Judy Reinhold  
Pediatric Nurse Practitioner, The Kelly O'Leary Center for ASDs, Division of Developmental and Behavioral Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Margaret W. Bultas  
Assistant Professor, School of Nursing, Saint Louis University, St. Louis, MO
Abstract

Introduction
The number of children with autism spectrum disorder (ASD) is rising, along with the potential for challenging behaviors during health care encounters.

Method
We present an overview of the emerging science related to ASD diagnosis and interventions for children with ASD.

Results
Emerging science on ASD reveals common associated challenging behaviors, increasing prevalence, emphasis on early diagnosis at 18 to 24 months of age, changes in the diagnostic process with criteria from the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, and interventions with medication, education, and behavior management.

Discussion
Family and health care provider preparation strategies facilitate care of children with ASD and their families. Early diagnosis at 18 to 24 months of age and evidence-based interventions contribute to best outcomes for children and families. Health care providers must be aware of the state of the science for diagnosis and best practices to provide family-centered care for this growing population.

Key Words
Autism spectrum disorder, autism, ASD, diagnosis, behavior

Autism spectrum disorder (ASD) is a developmental disorder that presents with atypical language and social behavior, along with restrictive and repetitive behaviors and unusual interests (American Psychiatric Association [APA], 2013). The spectrum of behaviors and their severity are highly variable (Hall, 2012). The behaviors may be self-inflicted (e.g., hitting or biting oneself) and/or externalized (e.g., hitting or kicking others; Johnson, Bekhet, Robinson, & Rodriguez, 2014; Matson et al., 2011). Behaviors may be exacerbated when children are stressed, such as in health care settings (Hall, 2012, Johnson and Rodriguez, 2013, Johnson et al., 2014, Matson et al., 2011).

Discerning the most accurate information about ASD to use as a basis for recommendations for family-centered ASD treatment can be challenging for nurse practitioners and other health care practitioners (HCPs), given the complexity of the symptoms and wide range of presentation (Lounds Taylor et al., 2012, Warren et al., 2011). The objective of this review article is to describe the evidence for the HCP's role in screening, the diagnostic process, and interventions with children who have ASD. We present background on the current state of the science related to ASD definition, associated behaviors, prevalence, the diagnostic process, and interventions.
ASD Definition

The definition of ASD has developed over time since it was introduced in the third edition of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-III; American Psychiatric Association [APA], 1980). Prior to 1980, ASD symptoms were considered to be representative of early onset schizophrenia (American Psychiatric Association, 1952, American Psychiatric Association, 1968). The fourth revision of the DSM categorized the symptoms of ASD into three distinct pervasive developmental disorders (PDDs): autism, PPD–not otherwise specified, and Asperger syndrome (APA, 1994). The classification of the PDDs did not change with the DSM IV–text revision (APA, 2000). With the fifth edition of the DSM, the three PDDs are collapsed into one diagnostic disorder, ASD. The diagnosis of Asperger syndrome and PDD–not otherwise specified are no longer given in the DSM-5. Future prevalence studies may be affected, given the change in the categorization of ASD with the DSM-5 (Swineford, Thurm, Baird, Wetherby, & Swedo, 2014).

The new DSM-5 diagnostic disorder ASD has two main criteria: (A) persistent social communication and social interaction deficits and (B) restricted, repetitive patterns of behavior, interests, or activities (see Box 1). A child may demonstrate all of the A criteria as early as age 2 years if the child does not respond to his or her name, has no or limited joint attention, and shows a lack of reciprocal interaction. An example of the B criteria in a toddler is an unusually strong interest in a play telephone during which time he does not engage with his mother, respond to his name, or share enjoyment with his mother about the phone. Adherence to restricted routines can lead to difficulties with transitions and challenging behaviors, such as tantrums (Weitlauf et al., 2014).

Box 1
Criteria for diagnosis of autism spectrum disorder

Criteria A: Persistent social communication and social interaction deficits in multiple contexts. Includes deficits in all three areas:
- Social-emotional reciprocity.
- Nonverbal communicative behaviors used for social interaction.
- Developing, maintaining, and understanding relationships.

Criteria B: Restricted, repetitive patterns of behavior, interests, or activities. Includes at least two:
- Stereotyped or repetitive movements, use of objects, or speech.
- Insistence on sameness, inflexible adherence to routines, or ritualized patterns of verbal or nonverbal behavior.
- Highly restricted, fixated interests that are abnormal in intensity or focus.
- Hyper- or hyporeactivity to sensory input or unusual sensory environment interest.

Criteria C: Symptoms were present in early developmental period.

Criteria D: Symptoms correlate with clinically significant impairments in social or occupational functioning.

Criteria E: Impairments are not better explained by intellectual disability or global developmental delay.

Clinician specifies the following:
- With or without intellectual impairment.
• With or without language impairment.
• Any associated or known medical or genetic condition.
• Any associated neurodevelopmental, mental or behavioral disorder.

Severity rating:
   Level 1: Requires support.
   Level 2: Requires substantial support.
   Level 3: Requires very substantial support.


The DSM-5 also requires clinicians to specify other diagnoses that may be present, such as cognitive or language impairment, known medical or genetic conditions, and other neurodevelopmental or behavior disorders (APA, 2013). The clinician rates the severity of the ASD on three levels. Level 1 requires support; level 2 requires substantial support; and level 3 requires very substantial support (APA, 2013).

Associated Behaviors
Challenging behaviors that accompany ASD are sometimes very difficult for families to manage. A variety of behaviors are associated with ASD. For example, aggression and self-injury have a significant impact on quality of life for children and families on the autism spectrum (Johnson, Frenn, Feetham, & Simpson, 2011). Anxiety is often seen to be a trigger for these behaviors (Davis et al., 2011). The anxiety can be linked to both receptive and expressive communication skill deficits that accompany ASD (Davis et al., 2010). Children with ASD also may have obsessive-compulsive features or the need for predictability and sameness. These characteristics can lead to some stressful situations for families (Miles, 2011).

Prevalence of ASD
Based on DSM-IV criteria, the prevalence of ASD in the United States is estimated to have increased from 1 in 10,000 people in the 1990s (Rutter, 2007) to 1 in 68 people (about 4.7 million) in 2014, with a 4:1 male to female prevalence (Baio et al., 2014). The broadening of the concept of autism in the DSM-IV to include Asperger syndrome increased the supports for ASD and the diagnostic surveillance in health and educational care. It also improved ASD awareness, which helps explain the increasing ASD prevalence (Baio et al., 2014, Fombonne, 2009, Rutter, 2007).

Some of the symptoms of ASD are subtle and therefore difficult to recognize on a consistent basis, which complicates the HCP's ability to recognize the earliest signs of ASD.

Some of the symptoms of ASD are subtle and therefore difficult to recognize on a consistent basis, which complicates the HCP's ability to recognize the earliest signs of ASD. This subtlety can add another layer of diagnostic uncertainty for the clinician working with the culturally diverse child. Although the ASD phenotype (i.e., how the child looks and behaves) does not differ by culture, the prevalence of ASD among diverse cultural groups differs significantly. White children have a 30%
greater prevalence for being diagnosed with ASD than African American children and a 50% greater prevalence than Hispanic children (Baio et al., 2014).

African American and Hispanic children are diagnosed with ASD on average 2.5 to 2.6 years later than White children (Kerfeld et al., 2011, Mandell et al., 2002, Mandell et al., 2009, Valicenti-McDermott et al., 2012). When African American and Hispanic children are diagnosed later, their ASD symptoms can be more severe, including poorer social reciprocity or the risk for an intellectual disability (Baio et al., 2014, Jarquin et al., 2011). Additionally, African American children with ASD are more often misdiagnosed with a behavioral disorder such as attention deficit hyperactivity disorder, adjustment disorder, or conduct disorder than are White children (Mandell, Ittenbach, Levy, & Pinto-Martin, 2007).

Lags in obtaining the ASD diagnoses for African American and Hispanic children can lead to preventable delays in implementing interventions to improve outcomes (Burkett, Morris, Manning-Courtney, Anthony, & Shambley-Ebron, 2015). These preventable delays represent a health care disparity in the United States. Multiple cultural factors contribute to lack of early diagnosis and lack of timely interventions for African American and Hispanic children with ASD, including (a) HCP diagnostic bias of the White male child, whose prevalence of diagnosis with ASD is typically higher than that of other ethnicities; (b) poorer health care accessibility than White children; (c) uncertainties about the presenting symptoms of African American and Hispanic children; and (d) family understanding of ASD symptoms (Mandell et al., 2007). When HCPs offer diagnostic and intervention care to families of culturally diverse backgrounds based on knowledge and understanding of these cultural factors, there exists a greater potential for reducing the gap of health care disparities for African American and Hispanic children with ASD (Burkett and Morris, 2015, Zuckerman et al., 2014).

The Diagnostic Process

Early Identification of ASD

Identification of ASD as early as 18 to 24 months of age is imperative so HCPs can direct families of children with ASD to evidence-based treatments for the best child and family outcomes (Weitlauf et al., 2014). Multiple studies have shown the effectiveness of early and intensive treatments on child outcomes in ASD (Dawson et al., 2010, Weitlauf et al., 2014). In response to this urgent need to recognize the signs of ASD early in a child's life, the Centers for Disease Control and Prevention (CDC) developed the “Learn the Signs Act Early” campaign, including a booklet listing normal child developmental milestones (Daniel, Prue, Taylor, Thomas, & Scales, 2009). An element of the campaign is the development and distribution of “Milestones booklets” that list the normal child developmental milestones. These booklets are available as a free download on the CDC Web site (http://www.cdc.gov/ncbddd/actearly/freematerials.html). To date, no research studies are available in the medical literature with regard to the effectiveness of this campaign.

The CDC also provides training video clips of the key early indicators of a risk for ASD to assist clinicians in the diagnostic process. The Learn the Signs Act Early Curriculum: Autism Case Training Videos (http://www.cdc.gov/NCBDDD/video/actearlycurriculum/index.html) are illustrative and promote understanding of the qualitative impairments of ASD, supplemented by the written text definitive criteria for ASD as outlined in the DSM-5 manual.
Primary care screening

Primary care providers screen for ASDs for children 18 and 24 months of age based on American Academy of Pediatrics (AAP) guidelines (Council on Children With Disabilities, 2006, Johnson and Myers, 2007). Numerous screening tools specific to ASD symptoms are available (Council on Children With Disabilities, 2006, Gardner, 2012, Zwaigenbaum, 2011). A commonly used tool is the Modified Checklist for Autism in Toddlers Revised Form (Herlihy et al., 2014, Robins et al., 2014). Primary care providers refer children for expert diagnostic evaluations if they appear to be at risk for ASD, based on this preliminary screening tool. Box 2 lists absolute “red flags” that should prompt referral for further diagnostic evaluation for ASD. These red flags are generally accepted by developmental specialists and are consistent with the social communication and restricted and repetitive behavior hallmarks of ASD. For children with positive ASD screening results and clinician concern, timely referral to both a developmental clinic for further diagnostic evaluations and referral to community early intervention program should occur simultaneously (Gardner, 2012, Johnson and Myers, 2007, Manning-Courtney et al., 2013).

Box 2

Absolute indications for referral for autism spectrum disorder diagnostic evaluation
No babbling by 12 months
No gesturing (e.g., pointing and waving bye-bye) by 12 months
No single words by 16 months
No two-word spontaneous (not echolalic) phrases by 24 months
Any loss of any language or social skills at any age

Expert Diagnosis

No medical or diagnostic markers exist to definitively diagnose ASD. The diagnostic process by experts involves comprehensive developmental screening by a multidisciplinary team of clinicians, including ASD-specific screening, which has been shown to be more reliable in detecting ASD than clinician observation alone (Daniels and Mandell, 2013, Guevara et al., 2013, Miller et al., 2011). The team evaluation consists of a developmental pediatric evaluation, administration of an ASD-specific diagnostic instrument, and a psychological evaluation. The developmental pediatric evaluation includes a detailed family, birth, medical, and developmental history, physical and neurologic examination, and developmental observations. The ASD-specific diagnostic instrument is the Autism Diagnostic Observation Schedule (ADOS), which is a standardized instrument that assesses social and communicative functions (Lord et al., 2012). Trained evaluators from any discipline such as speech and language, psychology, nursing, and education can administer the ADOS. The ASD-specific psychology evaluation includes standardized cognitive (intelligence quotient [IQ]), behavioral, emotional, and ASD-specific assessments.

Further medical evaluations are customized to the individual clinical situation. Because one early indicator of ASD is the inability of a child to orient to his or her name (Schaefer & Mendelsohn, 2013), all children should have an audiogram to rule out hearing loss as part of the effort to secure an accurate diagnosis. Children with significant hearing loss may display socialization and communication
difficulties and be misidentified as having ASD (Schaefer & Mendelsohn, 2013). After an accurate diagnosis, the primary care medical home provider should refer the child for genetics evaluation because ASD is thought to have a genetic basis (Schaefer & Mendelsohn, 2013).

Genetic and Genomics of Autism
The underlying cause of ASD and the subsequent challenging behaviors of children with ASD is the subject of much debate and research. It is commonly accepted that ASD is influenced by genetics (Buxbaum et al., 2014, Johnson et al., 2013b; Myers et al., 2011; Veenstra-Vanderweele et al., 2004), contributing factors in the environment (Shelton, Hertz-Picciotto, & Pessah, 2012), and maternal immune-mediated responses (Lyall, Ashwood, Van de Water, & Hertz-Picciotto, 2014). Researchers are studying several environmental factors that may affect gene expression and that also may modify gene expression via epigenetic changes (Shulha et al., 2012).

An international consortium of researchers has progressed in our understanding of ASD genetics by the use of candidate gene analysis, gene sequencing, and the study of copy number variants (CNVs; Buxbaum et al., 2014). Current research supports a major genetic contribution in children diagnosed with ASD in approximately 10% of children assessed by Fragile X testing and chromosome microarray analysis (Buxbaum et al., 2014). Fragile X, a single gene disorder affecting intellectual ability, is the most common single known cause of ASD (Kidd et al., 2014). Chromosome microarray analysis is a test that detects deletion or duplications of stretches of deoxyribonucleic acid known as CNVs. Chromosome microarray analysis is increasingly recommended in autism spectrum disorders (Peters & Pertile, 2014). Ongoing research seeks to determine new genetic biomarkers that measure the causes of ASD with more accuracy.

With the heterogeneity of ASD, it is difficult to tell how the genetic determinants affect socialization and behavior directly. Various models attempt to understand the connection of the ASD genotype to the phenotype. One model depicts ASD as a disturbance of physiological and behavioral rhythms that possibly affect the child's development of social communication impairments and repetitive behaviors and interests (Tordjman et al., 2015). For now, HCPs assess and treat the symptoms of the co-morbid conditions rather than treating ASD as a singular disorder. The identification of an underlying genetic disorder would help provide a unifying diagnosis for the child with ASD (Schaefer & Mendelsohn, 2013). Many syndromes have an established documented association with ASD (Johnson et al., 2013b, Schaefer and Mendelsohn, 2013; see Table 1). For these syndromes, no further investigation of the cause of the ASD is needed (Schaefer & Mendelsohn, 2013). There is no known cure for ASDs or consensus regarding the most effective intervention strategy (Myers & Johnson, 2007). Evidence suggests that only a minority of children progress to the point where they do not meet ASD diagnostic criteria (Fein et al., 2013).

### Table 1. Genetic disorders associated with autism spectrum disorder

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Incidence</th>
<th>% Co-occurring with ASD</th>
<th>Descriptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fragile X</td>
<td>1/3,600 males;</td>
<td>15-30 (Harris, 2011)</td>
<td>Single gene disorder affecting intellectual ability (Harris, 2011)</td>
</tr>
<tr>
<td></td>
<td>Females</td>
<td>Aged (Ref.)</td>
<td>Description</td>
</tr>
<tr>
<td>--------------------------</td>
<td>-----------------</td>
<td>-------------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Rett syndrome</strong></td>
<td>1/10,000 females</td>
<td>25-40 (Harris, 2011)</td>
<td>Regressive neurodevelopmental disorder of speech and unusual hand movement (Neul et al., 2010)</td>
</tr>
<tr>
<td><strong>Tuberous sclerosis</strong></td>
<td>1/6,000</td>
<td>25-60 (Harris, 2011)</td>
<td>Nonmalignant tumors primarily in the brain, eyes, and heart</td>
</tr>
<tr>
<td><strong>Down syndrome</strong></td>
<td>1/691</td>
<td>40 (Warner, Moss, Smith, &amp; Howlin, 2014)</td>
<td>Low muscle tone, small stature; more behavior problems than children with Down syndrome only (Warner, Moss, Smith, &amp; Howlin, 2014)</td>
</tr>
</tbody>
</table>

*Note. ASD = autism spectrum disorder.
Data from Siegel & Beaulieu, 2012.*

**Interventions**

Two systematic reviews of therapies for persons with ASD have been performed—one for children up to 12 years old (Weitlauf et al., 2014) and one for children ages 12 to 18 years (Lounds Taylor et al., 2012). Both reviews address areas for medical, educational, and behavioral interventions that may be used as evidence for clinical guidelines. In the review for the children aged 12 to 18 years, only five studies on medications were available, most of which were poor quality, pointing to a need for more research for this age group (Lounds Taylor et al., 2012).

Families typically choose which interventions to use for their child (Karst & Van Hecke, 2012) but tend to not have the time, resources, or expertise to consider all the options available (Stephenson, Carter, & Kemp, 2012). The high cost and variability in public funding and insurance coverage for some ASD interventions and complicated step-by-step formats of some interventions limit their feasibility and accessibility. As a result, parents may choose diets or medications not proven to be effective simply because they are straightforward interventions available at home (Lord & Bishop, 2010). Matson, Adams, Williams, and Rieske (2013) report that there is low parental adherence and compliance to medically prescribed treatments. In addition, parents may experience high levels of stress as a result of the child’s challenging behaviors. This stress takes a toll on the health of parents and may lead them to delay seeking care for their child (Bekhet et al., 2012, Cantwell et al., 2014, Johnson et al., 2011, Kerfeld et al., 2011, Lovell et al., 2012).

Recent literature highlights the importance of collaboration between parents and HCPs, known as shared decision making (SDM), for treatment selection, rather than simply expecting parent and child adherence to treatment recommendations (Institute of Medicine, 2015, Strauss et al., 2015, U.S. Department of Health and Human Services, 2010). Caregivers of children with ASD report a lack of SDM, difficulty accessing services, poor care coordination, and adverse family experiences compared with caregivers of children with developmental disabilities, mental health conditions, or both (Carbone et al., 2010, Vohra et al., 2014). Two inherent issues exist: limited SDM for ASD, and, even when SDM is present, a lack of HCPs who understand the complexity of parenting a child with ASD (Bultas, 2012, Johnson et al., 2011).
Medical and Related Interventions
Medical interventions target the symptoms of the developmental, psychiatric, neurologic, and gastrointestinal disorders that may co-occur with ASD (Levy et al., 2010). After receiving the medical diagnosis of ASD, children may be referred to specialists or an ASD center for ongoing developmental and medical follow up of co-occurring conditions. The focus in follow-up medical visits can often be problem-focused, reviewing with the family their day-to-day care of their child with ASD. As with many other chronic medical conditions, other medical problems can be seen that require acute episodic health care.

Seizures
Approximately 30% of children on the autism spectrum may have seizures sometime during their life (Tuchman, Moshe, & Rapin, 2009). Andell and colleagues (2015) reported that the most common neurodevelopment comorbidities of children 0 to 18 years (n = 766) who had a new-onset unprovoked seizure were developmental delay (22%; confidence interval [CI], 19% to 25%), speech/language and learning difficulties (23%; CI, 20% to 26%), and intellectual disability (16%; CI, 13% to 18%). Seizures were more common in older children with co-occurring psychiatric diagnosis (Andell et al., 2015). The onset of epilepsy peaks during adolescence and adulthood in ASD, for unknown reasons, and may be unique to children with ASD compared with other developmental disabilities (Tuchman et al., 2009).

Gastrointestinal disturbances
Research on specific gastrointestinal disorders that co-occur with ASD is limited. Gastrointestinal symptoms are difficult to evaluate because of the child's limited communication (Buie et al., 2010). Problem behavior in children with ASD may be the primary or sole symptom of an underlying gastrointestinal condition (Buie et al., 2010). Parents report that gastrointestinal issues are often the antecedent to challenging child behaviors and dysregulated sleep (Coury, Ashwood, et al., 2012). These conditions include gastroesophageal reflux disease, eosinophilic esophagitis, or and/or constipation (Coury, Ashwood, et al., 2012). Sensory integration differences may result in textural aversions to certain foods and a limited repertoire of food choices with a very selective diet (Badalyan and Schwartz, 2012, Chandler et al., 2013). The altered eating habits, along with psychopharmacological treatment, genetics, disordered sleep, and lack of adequate physical activity, contribute to the risk of obesity in this population (Curtin, Jojic, & Bandini, 2014). Children with ASD have a higher prevalence of obesity than the general population (Curtin, Anderson, Must, & Bandini, 2010).

Some parents of children with ASD try the gluten casein-free diet in an attempt to help improve their child's behavior. The diet is an exclusion diet that is costly and inconvenient. Evidence is lacking that following this diet improves a child's challenging behaviors and cognitive and social functioning (Millward, Ferriter, Calver, & Connell-Jones, 2008). Furthermore, following a gluten casein-free diet may place children at risk for suboptimal bone development (Geraghty, Depasquale, & Lane, 2010).

Pain sensitivity
In a systematic review of the pain of children with ASD, children with ASD were found to have different patterns of pain and discomfort expression than typically developing children. Instead of crying and seeking comfort, some children with ASD express pain differently (Allely, 2013). For example, some children with ASD who are in pain display the following: “furrowed brow,” “banging his/her head,” “injuring oneself,” “grimacing,” “guarding,” and “increased heart rate” (Inglese, 2008). Other identified
indicators of pain may be subjective and required (a) knowledge of the child’s baseline and (b) monitoring for changes from normal (i.e., “crankiness,” “being less active,” “rocking unusually,” “acting,” “off,” and “irritability”; Inglese, 2008). HCPs must be careful to not interpret this lack of typical finding as pain insensitivity or incorrectly assume that the child is in no pain (Allely, 2013). Close collaboration with parents to learn how their child expresses pain is indicated because some parents are able to describe unique behaviors that let them know when their child is in pain (Allely, 2013).

Medication Management of Symptoms of ASD
The use of medication in children with ASD is varied and usually symptom-specific. No medication has yet been developed that targets the core deficits seen in ASD—specifically, disordered language and social skill deficits. However, when concurrent medical symptoms are present, medications can be useful. The use of medication is carefully reviewed in the context of current health status and ongoing treatments. In determining a medication for behavior concerns, a careful history is needed to identify what may be triggering symptoms. For example, if anxiety seems to precede behavior outbursts, then anti-anxiety medication may be appropriate. The HCP should review with the family that the goal of medication treatment is to lessen the intensity of a symptom that may be interfering with the child’s ability to make progress. Deciding to begin a medication is often a “try and see” or trial approach, with a “start low and go slow” format for making dose adjustments (Reinhold & Manning-Courney, 2007).

Many children with ASD take psychotropic medications for challenging behaviors. In one study, Coury and colleagues determined the percentage of children with ASD (n = 2,853 children ages 3 to 17 years) who took at least one psychotropic medication by age range as follows: 11% of children aged 3 to 5 years; 46% of children aged 6 to 11 years; and 66% of children aged 12 to 17 years (Coury, Anagnostou, et al., 2012). Thus more teenagers are medicated than are children. The number of clinical trials of psychotropic medications continues to increase, which is helpful in guiding clinical practice. Measuring outcomes in the use of these medications continues to be difficult. Additionally, many medications in current use are considered “off-label,” without Food and Drug Administration (FDA) approval. However, avoiding agents that are off-label limits choices for potentially efficacious treatment. Currently, only two psychotropic medications, risperidone and aripiprazole, have FDA approval in the treatment of children with aggression and ASD (Weitlauf et al., 2014). Overall, medication combined with behavioral intervention appears to be more effective for reducing aggressive behavior than medication alone (Dawson & Burner, 2011).

Many children with ASD take psychotropic medications for challenging behaviors.

Some children on the autism spectrum have significant inattention, distractibility, and/or hyperactive behavior. Stimulant medications such as methylphenidate (Ritalin) diminish impulsivity and hyperactivity by blocking the reuptake of catecholamine (norepinephrine and dopamine) at the synaptic cleft (Purper-Ouakil, Ramoz, Lepagnol-Bestel, Gorwood, & Simonneau, 2011). Stimulants improve focus and decrease aggression for children with and without ADHD (Blader et al., 2013).

Table 2 lists common problems and psychotropic medications used in the treatment of ASD.

<table>
<thead>
<tr>
<th>Problem</th>
<th>Comments</th>
<th>Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-occurring conditions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and medications for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>autism spectrum disorder</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Co-occurring conditions, diagnostics, and medications for autism spectrum disorder
Anxiety and obsessive compulsive features

Medications are not the first line of treatment but may be helpful in lowering anxiety. SSRI medications have not been studied enough to know if they are helpful for ASD symptoms. SSRIs carry a black box warning. Benzodiazepines are used with caution because of the possibility of paradoxical effect and/or tolerance.

SSRIs: citalopram, clomipramine, desipramine, fluoxetine, fluvoxamine, paroxetine, and sertraline; An alternate anxiolytic, buspirone, has been used as an add-on medication or an alternative to the SSRI category.

Hyperactivity, distractibility, or inattention

Stimulant medications have not been studied enough to know if they are helpful for ASD symptoms. Atomoxetine cannot be crushed or sprinkled and takes several weeks for onset. Alpha 2 agonists (short and long acting) have been used off label and in younger children.


Aggression, agitation, self-injurious behavior

Only two medications approved for the treatment of agitation and aggression in children with ASD: risperidone and aripiprazole. Antipsychotics associated with weight gain, sleepiness, tremors and abnormal movements. Antiepileptic medications have been used to stabilize mood.


Seizures

1. EEG studies recommended for staring with unresponsiveness
2. Neuroimaging studies recommended if EEG abnormalities are present

Antiepileptic medications: lamotrigine, oxcarbazepine, valproate.

Note. ASD = autism spectrum disorder; EEG = electroencephalogram; SSRI = selective serotonin reuptake inhibitor.
Data from Siegel & Beaulieu, 2012.

Educational Intervention

The Individuals with Disabilities Education Improvement Act (IDEIA) mandates that parents of children aged 3 to 21 years with ASD be actively involved in decisions about the services and accommodations for their child through SDM (U.S. Department of Education, 2015). According to IDEIA, state departments of instruction are mandated to identify students with ASD and provide services in special education programs in the local school district for those older than 3 years. For children younger than 3 years, early intervention services are available throughout the United States, based in state county.
programs (U.S. Department of Education, 2015). Some children may only be diagnosed with ASD as part of a school evaluation rather than a formal evaluation for ASD. An educational diagnosis of ASD is based on the criteria from IDEIA (IDEIA, 2004). This educational ASD diagnosis can be quite helpful in guiding the child’s individualized educational plan.

Early intervention services must be provided in natural environments, including the home and community settings in which children without disabilities participate.

Early intervention services must be provided in natural environments, including the home and community settings in which children without disabilities participate. Parents of children with ASD are supported to help their children generalize skills learned at school into the home (Carter et al., 2013, Machalicek et al., 2008). Children receive other therapeutic interventions at school, such as speech and language therapy and occupational therapy for fine motor deficit and sensory integration difficulties (Weitlauf et al., 2014).

Behavioral Interventions

Numerous interventions have been designed to target the core features of ASD—that is, social communication and social interaction deficits and restricted, repetitive patterns of behavior, interests, or activities (see Table 3). Applied behavior analysis (ABA) is considered a best practice for the education of children with ASD, intellectual disability, and related disorders (Hagopian & Hardesty, 2015). ABA was first defined in 1968 as the process of systematically applying interventions based upon the principles of learning theory directed at improving the behavior (Baer, Wolf, & Risley, 1968).

Table 3. Select interventions for autism spectrum disorder

<table>
<thead>
<tr>
<th>Program</th>
<th>Select examples</th>
<th>Focus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early intensive behavioral intervention</td>
<td>1. Applied behavior analysis (Lovaas, 1987)</td>
<td>Overall development</td>
</tr>
<tr>
<td></td>
<td>2. Early Start Denver (Dawson et al., 2010)</td>
<td>Overall development, core symptoms, adaptive behavior</td>
</tr>
<tr>
<td></td>
<td>4. Floor time therapy derived from the Developmental Individual-Difference Relationship–based model (Wieder &amp; Greenspan, 2003)</td>
<td>Parent follows child’s lead</td>
</tr>
<tr>
<td></td>
<td>2. Facing your fears (Reaven, Blakeley-Smith, Leuthe, Moody, &amp; Hepburn, 2012)</td>
<td>Helps high-functioning children manage anxiety</td>
</tr>
<tr>
<td>Social skills programs</td>
<td>1. Skill streaming (Goldstein &amp; McGinnis, 1997)</td>
<td>Social skills, attention, play</td>
</tr>
</tbody>
</table>
ABA uses a behaviorist approach for either comprehensive or focused interventions (Hagopian & Hardesty, 2015). Comprehensive interventions aim to improve skills that have an impact on global measures of functioning over time, such as IQ, language/communication, socialization, discrimination, and attention (Hagopian & Hardesty, 2015). Small amounts of information are presented in repeated trials, using clear interactions, which are structured in a three-part contingency pattern (antecedent-response-consequence; Weitlauf et al., 2014). Comprehensive ABA is generally home based for 25 to 40 hours/week for several years (Hagopian & Hardesty, 2015). By contrast, focused interventions occur over a shorter amount of time. For example, a functional behavioral assessment to identify the variables antecedent to a problem behavior, such as aggression or self-injury, is considered a focused intervention (Hagopian & Hardesty, 2015).

Scientific support during the past 40 years links ABA-based procedures with reduction of problem behaviors and increasing appropriate skills (Hagopian & Hardesty, 2015). Research on children who received comprehensive ABA therapy for at least 8 months to 2 years showed greater improvements in cognitive performance, language skills, and adaptive behavior skills than broadly defined eclectic treatments available in the community (Weitlauf et al., 2014). A subset of all children who receive early intensive intervention showed significant improvement in terms of standardized outcomes, although many children continue to have substantial problems (Weitlauf et al., 2014). Research also shows promise for Naturalistic Developmental Behavioral Interventions (Schreibman et al., 2015), which use the principles of ABA in settings that are naturalistic, such as home and with a different arrangement of the three-part contingency. For example, a child may be placed in an environment (e.g., the kitchen) where he or she has to initiate an interaction with someone (e.g., ask for an apple) to get a desired item (apple) (Schreibman et al., 2015).

Some evidence suggests that improvements with ABA may vary with the underlying severity of the disorder, but more research for the correlates of improvement is needed (Weitlauf et al., 2014). Future research needs to look at how family functioning affects outcomes of ABA therapy and include measures of parental well-being (Howlin, Magiati, & Charman, 2009). Because family functioning affects child behaviors, all children who receive ABA therapy may not have acquired adequate adaptive behavior skills to cope with stressful acute episodic health care interactions. In an effort to help with family functioning, Autism Speaks has created tool kits with evidence-based guidance for parents with children with challenging behaviors (Autism Speaks, 2012) and ABA therapy (Autism Speaks, 2015). More information on the behavior management of children with ASD can be found in part 2 of this two-part publication on translating evidence to practice for children with ASD.

Conclusion
The research base representing the translation of evidence to practice for the health care of children with ASD is still a developing area of research. We presented background on the current state of the science related to ASD definition, associated behaviors, prevalence, diagnostic process, and
interventions. This evidence can inform health care institution clinical guidelines and policies. Future research is needed to test interventions that decrease children’s challenging behaviors and promote SDM among HCPs and families to optimize child and family health outcomes in health care settings.

References


Stephenson et al., 2012. J. Stephenson, M. Carter, C. Kemp. **Quality of the information on educational and therapy interventions provided on the web sites of national autism associations.** Research in Autism Spectrum Disorders, 6 (1) (2012), pp. 11-18


Tuchman et al., 2009. R. Tuchman, S.L. Moshe, I. Rapin. **Convulsing toward the pathophysiology of autism.** Brain Development, 31 (2) (2009), pp. 95-103


